Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Antiphospholipid Syndrome
•
General Rheumatology
•
APS
Is transdermal estrogen therapy safe for postmenopausal patients with positive antiphospholipid antibodies but no history of thrombosis or obstetric complications?
Related Questions
Do you avoid JAK inhibitors in patients with antiphospholipid antibodies and/or lupus anticoagulant given the potential risk of increased thromboembolic events with use of JAKi?
How do you approach recurrent migratory superficial thrombophlebitis in a patient with a negative malignancy workup and low-titer anticardiolipin antibodies?
Do you consider co-prescribing hormone therapy and anticoagulation in a patient with prior DVT and uncontrollable VSM uncontrolled by non-hormonal therapies?
Are there specific combinations of DMARDs and/or biologics that you avoid due to elevated infection risk or other safety concerns?
What is the role of inebilizumab in the maintenance treatment of IgG4-related disease?
How do you approach a patient with idiopathic anterior uveitis who has ongoing disease despite adalimumab every two weeks?
Do you have safety concerns when prescribing GLP-1 medications in patients on corticosteroids or immunosuppressive therapy?
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
How do you approach laboratory evaluation in patients with fatigue?
Do you regularly recommend an immunological workup for patients with suspected immunodeficiency or defer to immunology?
